GNPX (Genprex) Other Current Liabilities: $2.05 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GNPX Genprex Inc GNPX
33 GF Score
Price $3.99
! 1 Warning Sign
View Full Analysis

What is Genprex Other Current Liabilities?

Genprex GNPX +1.79% 33 Other Current Liabilities is $2.05 Mil as of Jun. 2026. GuruFocus rates GNPX with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Genprex's other current liabilities for the quarter that ended in Jun. 2026 was $2.05 Mil.

Genprex's quarterly other current liabilities increased from Dec. 2025 ($1.43 Mil) to Mar. 2026 ($1.70 Mil) and increased from Mar. 2026 ($1.70 Mil) to Jun. 2026 ($2.05 Mil).

Genprex's annual other current liabilities declined from Dec. 2023 ($1.86 Mil) to Dec. 2024 ($1.43 Mil) but then increased from Dec. 2024 ($1.43 Mil) to Dec. 2025 ($1.43 Mil).

Genprex Other Current Liabilities Related Terms

Genprex Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Genprex's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genprex Other Current Liabilities Chart

Genprex Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 2.37 1.86 1.43 1.43

Genprex Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.51 0.93 1.43 1.70 2.05
GNPX
33GF Score
Genprex Inc GNPX
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genprex Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $2.05 Mil mean?
Genprex (GNPX) has a Other Current Liabilities of $2.05 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Genprex.
Is Genprex's Other Current Liabilities too high?
Genprex's current Other Current Liabilities is $2.05 Mil. Overall, Genprex has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Genprex's Other Current Liabilities compare to SXTP and GLMD?
Genprex's Other Current Liabilities of $2.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Genprex. Genprex's current Other Current Liabilities is $2.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genprex stock overvalued right now?
Genprex (GNPX) has a current Other Current Liabilities of $2.05 Mil. The current Other Current Liabilities is $2.05 Mil. Genprex's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Genprex (GNPX), the current Other Current Liabilities is $2.05 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genprex Business Description

Other Exchanges 0A8I:UK
Address 3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
33GF Score

Get the complete analysis for GNPX

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.99
Price